StockNews.AI
TMO
StockNews.AI
8 days

Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment

1. TMO receives FDA approval for its Oncomine Dx Target Test for lung cancer detection. 2. This CDx approval may enhance TMO's market position in oncology diagnostics.

FDA Approval
+3.36%Current Return
VS
+0.8%S&P 500
$460.7208/11 08:42 AM EDTEvent Start
$476.1808/12 03:24 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

FDA approvals generally boost a company's credibility and potential revenue streams. Similar approvals have historically led to stock price increases for firms in the diagnostics sector.

How important is it?

The article highlights a significant FDA approval that can propel TMO's growth trajectory. Given the increasing demand for effective cancer diagnostics, this development is crucial.

Why Long Term?

The approval establishes a foundation for sustained growth in cancer diagnostics. Increased market share from effective diagnostics can lead to long-term revenue growth.

Related Companies

Boehringer Ingelheim
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epi.

Related News